Active material: Sodium picosulphate
When ATH: A06AB08
CCF: Laxatives, stimulating peristalsis
ICD-10 codes (testimony): K59.0, Z51.4
When CSF: 11.08.01
Manufacturer: BOEHRINGER INGELHEIM ITALY S.p.A. (Italy)
◊ Drops for intake as a clear, slightly viscous solution from colorless to yellowish.
| 1 ml (15 drops) | |
| sodium picosulphate | 7.5 mg |
Excipients: Sodium methyl parahydroxybenzoate, sorʙitola 70% solution, hydrochloric acid, Purified water.
15 мл – флаконы пластмассовые (1) с пробкой-капельницей – пачки картонные.
30 мл – флаконы пластмассовые (1) с пробкой-капельницей – пачки картонные.
Laxatives. Reduces the absorption of electrolytes and water, increases peristalsis. The active form of the drug is formed by hydrolysis under influence of intestinal microbes and directly excites the receptors of the intestinal wall, accelerating the promotion of intestinal contents.
Laxative effect develops through 10-12 h after administration.
After oral administration of sodium picosulphate is not absorbed from the gastrointestinal tract and is not exposed to liver-intestinal circulation.
- Atonic constipation;
- Regulation of the chair (hemorrhoids, proctitis, anal fissures);
- Preparation for surgery, instrumental and radiological studies.
The drug is taken before bedtime.
Adults administered in an initial dose of 10 drops, at Heavy and persistent constipation recommended dose up 30 drops.
Children under the age of 4 years administered in an initial dose of 5-10 drops.
Depending on the effect, obtained after administration of the initial dose of, on subsequent receptions dose increase or decrease.
From the digestive system: diarrhea, stomach ache.
Other: dehydration, violations of water-electrolyte balance, weakness, convulsions, decrease in blood pressure.
- Bowel obstruction;
- Strangulated hernia;
- Acute inflammatory diseases of the abdominal cavity (incl. peritonitis);
- Abdominal pain of unknown origin;
- Bleeding from the gastrointestinal tract;
- Spastic constipation;
- Severe dehydration;
- Metrorragija;
- Cystitis;
- I trimester of pregnancy;
- Children up to age 4 years;
- Hypersensitivity to sodium picosulphate and other ingredients.
FROM caution prescribers lactation.
There was no negative effect Guttalaks® on pregnancy and fetal development.
The drug is contraindicated in the I trimester of pregnancy. The need for Guttalaks® II and III trimesters is determined individually by the attending physician.
Sodium picosulphate not excreted in breast milk. Precautions should be prescribed the drug during lactation (breast-feeding).
IN experimental studies revealed no mutagenic and teratogenic effect of the drug.
Guttalaks® should not be taken without medical supervision more 10 days.
Symptoms: diarrhea, stomach ache, dehydration, violations of water-electrolyte balance, weakness, convulsions, decrease in blood pressure. Besides, in chronic overdose may develop ischemic colonic mucosa, secondary hyperaldosteronism, urolithiasis, of renal tubules.
Treatment: gastric lavage, correction of water and electrolyte balance, the use of antispasmodics.
In an application Guttalaks® and diuretics or corticosteroids increases the risk of electrolyte abnormalities.
Co-administration of broad-spectrum antibiotics may reduce the laxative effect Guttalaks®.
The drug is resolved to application as an agent Valium holidays.
The drug should be stored in a dark place at a temperature above 25 ° C; Do not freeze. Shelf life - 5 years.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More